Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.
about
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaTargeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapyCustomized targeted therapy in Hodgkin lymphoma: hype or hope?RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiationLow-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupCoordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases.Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaSirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaTesting of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated miceAlteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideComparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatSirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphomaNew agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.Exploiting cellular pathways to develop new treatment strategies for AML.Signal transduction inhibitor therapy for lymphoma.Emerging drugs for Waldenström's macroglobulinemia.Utility of mTOR inhibition in hematologic malignancies.Current status of targeted therapies for mantle cell lymphoma.The evolving landscape in the therapy of acute myeloid leukemia.Management of mantle cell lymphoma in the elderly: current and potential strategies.Use of mTOR inhibitors in the treatment of malignancies.mTORC signaling in hematopoiesis.The effects of pyrrolo[1,2-b][1,2,5]benzothiadiazepines in MEC1 cells.Novel agents in mantle cell lymphoma.NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.Activation of mTOR by human T-cell leukemia virus type 1 Tax is important for the transformation of mouse T cells to interleukin-2-independent growth.CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.Acetyl-lupeolic acid inhibits Akt signaling and induces apoptosis in chemoresistant prostate cancer cells in vitro and in vivo.
P2860
Q24607479-55AB82DB-A7C4-46AC-B27D-0EB2AEBE82C3Q24632296-3A512287-D1A4-4A60-A8AD-3B38160FDE13Q27002554-532893C0-1DFE-4845-9275-396A6C4DD841Q28396305-7019A058-83AC-4A2D-A3D8-54E36F4D16A7Q33379949-5DE4E8B2-8064-42AF-AE32-60E4A390DA89Q34243327-47836BFB-014A-46FA-B59A-50B772BECB66Q34249719-BA1BF99F-86B7-43B2-928D-8BA3DA1F340FQ34617756-D8C638A4-6A4E-4DA6-8E4D-612B0BA484A7Q35231363-1A8657D6-5B8A-497F-A84E-273D42BA7157Q35651754-333B01B2-0E8A-46B5-88B7-42467F7B3B50Q35791105-22364A19-FE4D-49C5-BF10-CDCCBADA6D20Q36289873-98ED98B1-B6F1-4C84-A405-ECDBE3F45837Q36899362-08A52B1D-660D-46E1-86F0-F5273A1BBA41Q36973814-04560266-A066-44CF-9646-AED75223038EQ37051428-7F9459F7-8A41-4B6F-9CA6-1DDE08B1E1BAQ37074284-34F93FDF-1CC0-4FDE-BAD4-50BB5FEE9966Q37109227-AC8D653F-7D09-4615-B36B-BE712B97ACB2Q37201853-66AC9E97-B591-4C5A-BA85-9C9748E55FA3Q37238884-32CCAD26-F7C4-4E22-B012-7B98D63C5B7EQ37247581-BB470059-0E18-4C02-8414-4CDB5B6D1EBCQ37320140-9E9BEB97-5DBF-4127-9016-FDFD39574925Q37321798-6AAFC405-57DD-4E0F-AD45-5A707A5061ABQ37579286-461B04E7-0004-44A5-A4AE-B64821B7DD9DQ37586897-FA745AA6-008D-4672-8B89-188BBC18D6A2Q37598141-271ABFBE-5E0F-4431-8E7E-44BE9A2C8D0CQ37670417-E909D424-13BC-4607-9099-3B3F60F9E3B9Q37829224-4176F173-74EF-418C-9306-D354DD554866Q37847176-DEFD6AC0-A66B-423A-9B45-AD6EE88F5724Q37883723-C1DB305B-9A48-4E71-84A5-BA4F9D66039FQ37956405-D171D674-25D9-4D52-9C79-2D6DAB000DCFQ38132064-28BE8416-E7EE-4316-AF73-AFD7C5D06270Q38157682-BC6DD7DD-62F7-4FB6-8A63-4EAAEB3E9822Q38199196-E9D81A46-F1B2-418F-BA13-682834CD0695Q38704683-58B75B57-FDC1-4223-BEDF-4319AD986763Q38957465-00AA3F4E-4A6E-4C5A-B270-55AB8CEA9CFDQ39290199-13F7B218-54B8-433F-8E30-D3BB7104D734Q39291545-C55A85BB-D0B8-49C0-8619-6C3A2B991695Q39456041-B71C0EC3-C6BD-4911-90A7-6F72193A8542Q39642145-801FD22C-6F01-46D1-A0AC-B3390DFFB9D5Q41549361-EFF357E8-CE26-491A-BF8A-5B066D87737B
P2860
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Inhibition of the phosphatidyl ...... y in hematologic malignancies.
@ast
Inhibition of the phosphatidyl ...... y in hematologic malignancies.
@en
type
label
Inhibition of the phosphatidyl ...... y in hematologic malignancies.
@ast
Inhibition of the phosphatidyl ...... y in hematologic malignancies.
@en
prefLabel
Inhibition of the phosphatidyl ...... y in hematologic malignancies.
@ast
Inhibition of the phosphatidyl ...... y in hematologic malignancies.
@en
P1476
Inhibition of the phosphatidyl ...... ay in hematologic malignancies
@en
P2093
Thomas E Witzig
P2888
P304
P356
10.1007/S11864-006-0038-1
P577
2006-07-01T00:00:00Z